tiprankstipranks
Immunocore Holdings (IMCR)
NASDAQ:IMCR

Immunocore Holdings (IMCR) Stock Forecast & Price Target

121 Followers
See the Price Targets and Ratings of:

IMCR Analyst Ratings

Strong Buy
12Ratings
11 Buy
1 Hold
0 Sell
Based on 12 analysts giving stock ratings to
Immunocore
Holdings
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

IMCR Stock 12 Months Forecast

Average Price Target

$84.27
▲(29.65% Upside)
Based on 12 Wall Street analysts offering 12 month price targets for Immunocore Holdings in the last 3 months. The average price target is $84.27 with a high forecast of $92.00 and a low forecast of $63.00. The average price target represents a 29.65% change from the last price of $65.00.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"plus_tr_sans","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"45":"$45","57":"$57","69":"$69","81":"$81","93":"$93"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":92,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n  <span style=\"color:#199ca5\">$92.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":84.27,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n  <span style=\"color:#828080\">$84.27</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":63,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n  <span style=\"color:#912767\">$63.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[45,57,69,81,93],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2023","6":"Sep<br/>2023","9":"Dec<br/>2023","12":"Mar<br/>2024","25":"Mar<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,67.41,69.30153846153846,71.19307692307692,73.08461538461538,74.97615384615385,76.86769230769231,78.75923076923077,80.65076923076923,82.54230769230769,84.43384615384616,86.32538461538462,88.21692307692308,90.10846153846154,{"y":92,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,67.41,68.70692307692308,70.00384615384615,71.30076923076923,72.5976923076923,73.89461538461538,75.19153846153846,76.48846153846154,77.78538461538461,79.0823076923077,80.37923076923076,81.67615384615384,82.97307692307692,{"y":84.27,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,67.41,67.07076923076923,66.73153846153846,66.3923076923077,66.05307692307692,65.71384615384615,65.37461538461538,65.03538461538461,64.69615384615385,64.35692307692308,64.0176923076923,63.67846153846154,63.33923076923077,{"y":63,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":46.71,"date":1679616000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.57,"date":1680825600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":59.83,"date":1683244800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":56.35,"date":1685664000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":62.26,"date":1688688000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.14,"date":1691107200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.27,"date":1693526400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.28,"date":1696550400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":49.15,"date":1698969600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":52.64,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66.55,"date":1704412800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":73.74,"date":1706832000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":67.41,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$92.00Average Price Target$84.27Lowest Price Target$63.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Robert W. Baird
$84.00
Buy
29.23%
Upside
Reiterated
02/28/24
Analysts Are Bullish on Top Healthcare Stocks: Jazz Pharmaceuticals (JAZZ), Oculis Holding (OCS)
Capital One Financial
$89.00
Buy
36.92%
Upside
Reiterated
02/28/24
Analysts Offer Insights on Healthcare Companies: Sarepta Therapeutics (NASDAQ: SRPT) and Immunocore Holdings (NASDAQ: IMCR)
Cantor Fitzgerald
Buy
Initiated
11/02/23
Immunocore initiated with an Overweight at Cantor FitzgeraldImmunocore initiated with an Overweight at Cantor Fitzgerald
Morgan Stanley
$79.00
Buy
21.54%
Upside
Reiterated
08/22/23
Analysts Conflicted on These Healthcare Names: Galapagos (NASDAQ: GLPG) and Immunocore Holdings (NASDAQ: IMCR)
Guggenheim
$85.00
Buy
30.77%
Upside
Initiated
03/30/23
Immunocore initiated with a Buy at GuggenheimImmunocore initiated with a Buy at Guggenheim

Best Analysts Covering Immunocore Holdings

Which Analyst Should I Follow If I Want to Buy IMCR and Sell After:
1 Month
Patrick TrucchioH.C. Wainwright
Success Rate
8/16 ratings generated profit
50%
Average Return
+6.54%
reiterated a buy rating 24 days ago
Copying Patrick Trucchio's trades and holding each position for 1 Month would result in 50.00% of your transactions generating a profit, with an average return of +6.54% per trade.
dummydummy
Success Rate
0/0 ratings generated profit
0%
Average Return
0.00%
a rating ―
Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.
Premium Content
Find out which analyst has the highest Average Return & Success Rate
Go Premium
3 Months
Patrick TrucchioH.C. Wainwright
Success Rate
12/16 ratings generated profit
75%
Average Return
+22.77%
reiterated a buy rating 24 days ago
Copying Patrick Trucchio's trades and holding each position for 3 Months would result in 75.00% of your transactions generating a profit, with an average return of +22.77% per trade.
dummydummy
Success Rate
0/0 ratings generated profit
0%
Average Return
0.00%
a rating ―
Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.
Premium Content
Find out which analyst has the highest Average Return & Success Rate
Go Premium
1 Year
Justin KimOppenheimer
Success Rate
7/8 ratings generated profit
88%
Average Return
+19.54%
reiterated a buy rating 30 days ago
Copying Justin Kim's trades and holding each position for 1 Year would result in 87.50% of your transactions generating a profit, with an average return of +19.54% per trade.
2 Years
Jessica FyeJ.P. Morgan
Success Rate
9/9 ratings generated profit
100%
Average Return
+38.61%
reiterated a buy rating 10 days ago
Copying Jessica Fye's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +38.61% per trade.
dummydummy
Success Rate
0/0 ratings generated profit
0%
Average Return
0.00%
a rating ―
Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.
Premium Content
Find out which analyst has the highest Average Return & Success Rate
Go Premium
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

IMCR Analyst Recommendation Trends

Rating
Oct 23
Nov 23
Jan 24
Feb 24
Mar 24
Strong Buy
6
10
9
6
0
Buy
12
5
11
19
19
Hold
0
0
0
1
1
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
18
15
20
26
20
In the current month, IMCR has received 19 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. IMCR average Analyst price target in the past 3 months is $84.27.
Each month's total comprises the sum of three months' worth of ratings.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

IMCR Financial Forecast

IMCR Earnings Forecast

Next quarter’s earnings estimate for IMCR is -$0.36 with a range of -$0.47 to -$0.10. The previous quarter’s EPS was -$0.40. IMCR beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.27% of the time in the same period. In the last calendar year IMCR has Underperformed its overall industry.
Next quarter’s earnings estimate for IMCR is -$0.36 with a range of -$0.47 to -$0.10. The previous quarter’s EPS was -$0.40. IMCR beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.27% of the time in the same period. In the last calendar year IMCR has Underperformed its overall industry.

IMCR Sales Forecast

Next quarter’s sales forecast for IMCR is $70.75M with a range of $63.09M to $95.79M. The previous quarter’s sales results were $70.77M. IMCR beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 47.05% of the time in the same period. In the last calendar year IMCR has Outperformed its overall industry.
Next quarter’s sales forecast for IMCR is $70.75M with a range of $63.09M to $95.79M. The previous quarter’s sales results were $70.77M. IMCR beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 47.05% of the time in the same period. In the last calendar year IMCR has Outperformed its overall industry.

IMCR Stock Forecast FAQ

What is IMCR’s average 12-month price target, according to analysts?
Based on analyst ratings, Immunocore Holdings’s 12-month average price target is $84.27.
    What is IMCR’s upside potential, based on the analysts’ average price target?
    Immunocore Holdings has 29.65% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is IMCR a Buy, Sell or Hold?
          Immunocore Holdings has a conensus rating of Strong Buy which is based on 11 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Immunocore Holdings’s price target?
            The average price target for Immunocore Holdings is $84.27. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $92.00 ,the lowest forecast is $63.00. The average price target represents 29.65% Increase from the current price of $65.
              What do analysts say about Immunocore Holdings?
              Immunocore Holdings’s analyst rating consensus is a Strong Buy. This is based on the ratings of 12 Wall Streets Analysts.
                How can I buy shares of IMCR?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis